We are here to serve you with the opportunities of getting good jobs in Pharma , also we serve the best people for your organization. Our goal is to bring whole Pharma industries in one family where not even experienced but fresher also get opportunity to get into this Pharma world. We will give you opportunity to plant your own PHARMA TREE, so that you become the part of this Pharma world and get whenever and whatever you want

                                                                         PHARMAATREE                                                                                                                                                PLANT YOUR OWN TREE         

Mylan introduces new generic contraceptive pill in USBy PBR Staff Writer
Mylan Pharmaceuticals has introduced Norethindrone Tablets USP, 0.35mg, which is the generic version of Watson Laboratories' (now Actavis) Nor-Q.D. tablets, 0.35mg for 28-day cycle, for the prevention of pregnancy in the US. 
Drug Research > Drug Discovery & Development >


Iroko announces FDA acceptance of Indomethacin NDA filingBy PBR Staff Writer

Specialty pharmaceutical company Iroko Pharmaceuticals has announced the FDA acceptance for New Drug Application (NDA) filing of lower dose submicron Indomethacin, a non-steroidal anti-inflammatory drug. 


Marinomed pharma grants rights to antiviral products for ChinaBy PBR Staff Writer
Viennese biotech company Marinomed Biotechnologie has licensed the rights of five drugs to a global pharmaceutical firm for the Chinese market. 


Probi and BiO-LiFE partner to launch probiotic medicine in MalaysiaBy PBR Staff Writer
Swedish company Probi and BiO-LiFE, a healthcare company in vitamin and dietary supplements category, have entered into a partnership agreement to launch a probiotic product within the gastrointestinal field in Malaysia.
Production & Manufacturing > OTC > NewsRafarma signs Imatinib production contract with JSC F-SynthesisBy PBR Staff Writer
Rafarma Pharmaceuticals, a producer of generic antibiotic and specialty pharmaceuticals, has signed a new exclusive contract with JSC F-Synthesis for the production of the oral anti-cancer drug Imatinib. 
Production & Manufacturing > Process & ProductionNewsGenzyme gains rights to Asklepios' duplex gene therapy vector technologyBy PBR Staff Writer
Asklepios BioPharmaceutical has signed a non-exclusive cross-license agreement that provides Genzyme, a Sanofi company, with rights to its duplex gene therapy vector technology. 
Contract Research & Services > Contract Services >

Cipla - Indian pharma companies have better prospects overseas--

Top Court in India Rejects Novartis Drug Patent--

Top Headline-
 

Pharmaceutical Business Review

Cipla completes acquisition of Cipla Medpro South Africa for $456.43mIndian based pharmaceutical company Cipla has completed the acquisition of Cipla Medpro South Africa for a consideration of ZAR4.507bn ($456.43m).Inward Investment > News
 
 

Cipla completes acquisition of Cipla Medpro South Africa for $456.43m

PBR Staff WriterPublished 17 July 2013
 

Indian based pharmaceutical company Cipla has completed the acquisition of Cipla Medpro South Africa for a consideration of ZAR4.507bn ($456.43m).

 

Commenting on the development Cipla managing director and global CEO Subhanu Saxena was quoted by The Economic Times as saying that the investment is aligned with the company's strategy to ascend the value-chain by managing a front end sales force in a market outside India.

"The acquisition aims to further strengthen Cipla's commitment to South Africa and the broader African continent," Saxena added.

"The integrated business will compete more effectively in the changing local and global pharmaceutical environments and as such there will be an increasing focus on key African markets."

Earlier in November 2012, the company offered Cipla Medpro the acquisition of 51% stake at a rate of ZAR8.55 per share.

Durban-based Cipla Medpro Manufacturing is one of the two major divisions of the South African pharma company, while Cape Town-based Cipla Medpro is the second one.

A range of medicines and products against a number of critical care areas, including cardiovascular and respiratory, diabetes, oncology, psychiatry, anti-malarials and HIV/AIDS are offered by Cipla Medpro.

 


`IMITINEF MERCILET` is a medicine which cures blood cancer. Its available free of cost at "Adyar Cancer Institute in Chennai".
Cancer Institute  - Adyar, Chennai, 
Category :  Cancer
Address : East Canal Bank Road, Gandhi Nagar
                 Adyar, Chennai -600020
Landmark: Near Michael School
Phone : 044-24910754  044-24910754 ,  044-24911526  044-24911526 , 044-                  22350241  044-22350241

 

Planet hope - India: the generic drug war--

Fish oil supplements may help fight against Type 2 diabetes

Friday, 24 May 2013

Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Fish oil supplements, also called omega 3 fatty acid capsules, raise levels of adiponectin in the bloodstream. Adiponectin is an important hormone that has beneficial effects on metabolic processes like glucose regulation and the modulation of inflammation. In long-term human studies, higher levels of adiponectin are associated with lower risks of type 2 diabetes and coronary heart disease.

"While prior animal studies found fish oil increased circulating adiponectin, whether similar effects apply in humans is not established," said the study's lead author, Jason Wu, PhD, of the Harvard School of Public Health. "By reviewing evidence from existing randomized clinical trials, we found that fish oil supplementation caused modest increases in adiponectin in the blood of humans.

 

FDA Approved Drugs

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to help assist in your search.

Join our Drug Research Updates group on LinkedIn! 

Find out moreabout the types of drugs included in this listing.

2013

Cardiology/Vascular Diseases

Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013

Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyoerlipidemia, Approved May 2013

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Dermatology

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Devices

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2013

Endocrinology

Invokana (canagliflozin); Janssen Pharmaceuticals; For the treatment of type II diabetes mellitus, Approved April 2013

Nesina (alogliptin); Takeda; For the treatment of type II diabetes mellitus, Approved January 2013

Osphena (ospemifene); Shionogi; For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013

Family Medicine

Actemra ((ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2013

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013

Invokana (canagliflozin); Janssen Pharmaceuticals; For the treatment of type II diabetes mellitus, Approved April 2013

Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyoerlipidemia, Approved May 2013

Nesina (alogliptin); Takeda; For the treatment of type II diabetes mellitus, Approved January 2013

Osphena (ospemifene); Shionogi; For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol); Teva Pharmaceutical; For the prevention of contraception, Approved April 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Tecfidera (dimethyl fumarate); Biogen Idec; For the treatment of relapsing multiple sclerosis, Approved March 2013

Uceris (budesonide); Santarus; For the treatment of ulcerative colitis, Approved January 2013

Gastroenterology

Stivarga (regorafenib); Bayer; For the treatment of gastrointestinal stromal tumor, Approved February 2013

Uceris (budesonide); Santarus; For the treatment of ulcerative colitis, Approved January 2013

Genetic Disease

Kineret, anakinra; Swedish Orphan Biovitrum; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013

Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013

Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics; For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013

Healthy Volunteers

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Hematology

Kcentra (Prothrombin Complex Concentrate); CSL Behring; For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Pomalyst (pomalidomide); Celgene; For the treatment of relapsed and refractory multiple myeloma, Approved February 2013

Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics; For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013

Immunology

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Kineret, anakinra; Swedish Orphan Biovitrum; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Tecfidera (dimethyl fumarate); Biogen Idec; For the treatment of relapsing multiple sclerosis, Approved March 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

Infections and Infectious Diseases

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

Musculoskeletal

Actemra ((ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013

Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013

Tecfidera (dimethyl fumarate); Biogen Idec; For the treatment of relapsing multiple sclerosis, Approved March 2013

Nephrology

Procysbi (cysteamine bitartrate); Raptor Pharmaceuticals; For the management of nephropathic cystinosis, Approved May 2013

Neurology

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Nutrition and Weight Loss

Nesina (alogliptin); Takeda; For the treatment of type II diabetes mellitus, Approved January 2013

Obstetrics/Gynecology (Women’s Health)

Kadcyla (ado-trastuzumab emtansine); Genentech; For the treatment of HER2-positive metastatic breast cancer, Approved February 2013

Osphena (ospemifene); Shionogi; For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol); Teva Pharmaceutical; For the prevention of contraception, Approved April 2013

Oncology

Kadcyla (ado-trastuzumab emtansine); Genentech; For the treatment of HER2-positive metastatic breast cancer, Approved February 2013

Pomalyst (pomalidomide); Celgene; For the treatment of relapsed and refractory multiple myeloma, Approved February 2013

Stivarga (regorafenib); Bayer; For the treatment of gastrointestinal stromal tumor, Approved February 2013

Xofigo (radium Ra 223 dichloride); Bayer Healthcare Pharmaceuticals; For the treatment of prostate cancer with bone metastases, Approved May 2013

Pediatrics/Neonatology

Actemra ((ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013

Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013

Kineret, anakinra; Swedish Orphan Biovitrum; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013

Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013

Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics; For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013

Pharmacology/Toxicology

Kcentra (Prothrombin Complex Concentrate); CSL Behring; For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013

Pulmonary/Respiratory Diseases

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2013

Rheumatology

Actemra ((ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013

Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013

Trauma (Emergency, Injury, Surgery)

Kcentra (Prothrombin Complex Concentrate); CSL Behring; For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013

Urology

Xofigo (radium Ra 223 dichloride); Bayer Healthcare Pharmaceuticals; For the treatment of prostate cancer with bone metastases, Approved May 2013

Vaccines

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

 

AstraZeneca first quarter results 2013

Thursday, 25 April 2013

AstraZenecaAstraZeneca today announced that the revenue for the first quarter was $6,385 million, down 12 percent at constant exchange rates (CER). Losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada, were the key drivers for the revenue decline. Growth for Symbicort, Brilinta, Iressa and the inclusion of the Amylin diabetes products delivered more than $250 million of revenue growth at CER in the quarter.

Pharmaceutical Business Review

FDA approves Raptor's Procysbi delayed release capsules The US Food and Drug Administration (FDA) has approved Raptor's Procysbi (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children six years and older.  

 

 

Intas launches low cost drug for cancer treatment ET 30 Apr 2013, 18:50 IST

AHMEDABAD: Intas Pharmaceutical today said it has launched 'Mabtas' a new low cost drug for treating cancer in India. "Mabtas, is a biosimilar version of Rituximab, a type of protein therapy for treatment of cancer.

 

Healthcare in India needs intensive care ET 08 Apr 2013, 05:12 IST

Healthcare in India needs intensive care

If there is one message from the Supreme Court verdict on Novartis, it is this: India needs to place health at the centre of its development. The struggle is not about a patent or two. It is about the health of a nation.

 Novartis SME News, Wednesday, Apr 03, 2013
  New Delhi: A day after India's Supreme Court dismissed Swiss pharma firm Novartis AG's petition for patent for its anti-cancer drug, the Swiss envoy on Tuesday said concerns related to patents need to be tackled by companies.

 

Pharmaceutical Industry News

phrama firmsSME News, Tuesday, Apr 16, 2013
MUMBAI: In an attempt to boost export business of small and medium pharma firms, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) has announced its plans to set up warehouse facilities in Latin America, Africa and Europe.

 

vaccinesSME News, Friday, Apr 19, 2013
SOLAN: India must become the leader of low-cost vaccines for HIV, cancer and Malaria, and further target producing 20 per cent of world generics drugs by 2020, the former President A P J Kalam said.   Kalam stated, "India is rich in bio-diversity.

 

Zydus Wellness awarded ‘Product of the Year 2013’

 

Mr. Ganesh Nayak, COO & Executive director received the award on behalf of the entire Zydus team from Nandan Nilekani at the special award ceremony held in Mumbai

 Zydus Wellness Ltd, has been awarded the ‘Product of the Year 2013’ for their premium table spread product ‘Nutralite Omega 3’. Mr Ganesh Nayak, COO & Executive director received the award on behalf of the entire Zydus team from Nandan Nilekani at the special award ceremony held in Mumbai.

 

GlaxoSmithKline launches Sensodyne Repair & Protect

The brand Sensodyne itself has been boosting the growth of the premium oral care category in India since its launch; in just over two years of its national launch, Sensodyne has become the number one sensitive toothpaste in India!

 

Sensodyne, GlaxoSmithKline’s (GSK) leading global brand for sensitive teeth, today announced the launch of Sensodyne “Repair & Protect” – a unique offering that further strengthens its positioning as the sensitivity expert. Sensodyne Repair & Protect provides a higher order benefit of repair as it repairs areas of the tooth that are susceptible to sudden twinges of sensitivity with daily use. Powered with patented Novamin technology - a breakthrough clinically proven formula - it helps in repairing vulnerable sensitive areas with the natural building blocks of your teeth.

 

 

48th Indian Orthodontic Conference 2013

Conference

22nd   to  24th November 2013
Ahmedabad, Gujarat, India

Website: http://www.48ioc.com
Contact person: Dr Kalyani Trivedi

The GOSG is a 90 member strong study group established in 1990. This is the oldest group after the Bombay study group. The conference comes to Ahmedabad after a gap of almost 35 years.

Organized by: Indian Orthodontic Society
Deadline for abstracts/proposals: 21st November 2013


 

 

4th International Conference on Stem Cells and Cancer (ICSCC-2013): Proliferation, Differentiation and Apoptosis

Conference

19th   to  22nd October 2013
Mumbai, Maharashtra, India

Website: http://www.icscc.in/
Contact person: Prof. Dr. Sheo Mohan Singh

Covers basic/applied research on proliferation, differentiation & apoptosis of stem & cancer cells, stem cell therapy, clinical trials on stem cells, cancer diagnostics, anti-cancer drugs, cancer therapeutics, HSC, iPSC, MSC, cancer stem cells etc.

Organized by: International Centre for Stem Cells, Cancer and Biotechnology (ICSCCB), Pune, India




IFASCON-2013
Indian Foot and Ankle Society Conference

30th Aug - 1st Sep, 2013

Contact: Dr Balvinder Rana
Venue: Gurgaon, India
M: 9873020484
E: ifascon2013@gmail.com

http://ifascon2013.com

 

IOACON 2013
Annual Conference of The Indian Orthopaedic Association

3 - 8th Dec, 2013

Contact: Dr. Sanjay Chaturvedi
Venue: Jaypee Palace Hotel & International Convention Centre, Agra
M: +91 94122 61575
E: secretariat@ioaconagra.org

http://www.ioaconagra.org







   





 

October 2013

24th

18th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) Vienna, Austria

   

November 2013

21st

5th Asia Pacific Congress on Building Consensus out of Controversies in Gynecology, Infertility and Perinatology (BCGIP-cogi) Shanghai, China